Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSNUVZ)

• Drug Name: PMID25656651-Compound-19a Drug Info
• Cross-matching ID:
  PubChem CID: 42613483
  TTD Drug ID: DMSNUVZ

Molecule-Related Drug Atlas

Drug(s) Targeting Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID25656651-Compound-37b	DMX98YV	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-36a	DMNXVY9	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-37c	DM684IK	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-36d	DMKMY4I	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-36b	DMHYDM7	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-36c	DMOGKSW	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-19b	DMI1Z7D	N. A.	N. A.	Patented	[1]
PMID25656651-Compound-37a	DM0P4F3	N. A.	N. A.	Patented	[1]
Indazole derivative 5	DMM1I8R	N. A.	N. A.	Patented	[1]
Pyrrolo[2,3-b]pyridine derivative 4	DMJBTZG	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Fusion protein Bcr-Abl (Bcr-Abl)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[2]
Nilotinib	DM7HXWT	Chronic myelogenous leukaemia	2A20.0	Approved	[3]
Asciminib	DM7EVUF	Chronic myeloid leukaemia	2A20	Approved	[4]
Radotinib	DMWA74Y	leukaemia	2A60-2B33	Phase 3	[5]
ABL 001	DMMF5K4	Chronic myeloid leukaemia	2A20	Phase 3	[6]
ICLUSIG	DM1SQSE	Acute lymphoblastic leukaemia	2A85	Phase 3	[7]
Bafetinib	DM7586F	Bone disease	FC0Z	Phase 2	[8]
AN-019	DMJ7QP8	Chronic myelogenous leukaemia	2A20.0	Phase 2	[9]
HQP1351	DMQ30X2	Chronic myeloid leukaemia	2A20	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fusion protein Bcr-Abl (Bcr-Abl)	TTS7G69	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[1]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[1]

References

• [1] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [2] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [3] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [4] Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
• [5] Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
• [6] ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
• [7] Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 Jul 26;132(4):393-404.
• [8] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [9] Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
• [10] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.